Financial Health Assessment: Galson Sciences Limited

1. Financial Health Score: C+

Explanation: The patient is in a state of partial recovery following a severe financial event between 2020-2022 that saw shareholder value haemorrhage from £8.6M to £540K. While 2023 shows encouraging vital signs with a 55% recovery in equity and doubled cash reserves, the company remains a shadow of its former financial health. The current liquidity position is adequate but not robust, and the dramatic increase in short-term creditors warrants careful monitoring. The backing of French parent Egis Industries SAS provides a safety net, but the company's standalone health remains compromised.

2. Key Vital Signs

Heart Rate: Liquidity Ratios

Interpretation: The patient's circulatory system—its ability to circulate cash to meet obligations—has improved but remains under strain. The current ratio of 1.52 means the company has £1.52 in current assets for every £1 of short-term debts. This is at the lower end of the healthy range, suggesting limited buffer for unexpected demands.

Blood Pressure: Leverage & Solvency

Interpretation: Blood pressure is elevated. The company owes £1.88 for every £1 of shareholder equity—this has worsened from 1.59 in 2022. While the upward trajectory in equity is positive, the faster growth in liabilities is concerning and suggests the recovery is being partially financed by increased creditor dependence.

Temperature: Cash Health

Interpretation: The patient's temperature has stabilized and is trending toward normal. Cash has nearly doubled year-on-year, and the proportion of current assets held in liquid form has improved. This indicates stronger cash generation from operations.

Respiratory Rate: Working Capital Cycle

Interpretation: The patient is breathing faster—both money coming in and going out have accelerated significantly. The 58% increase in trade debtors and 36% increase in contract recoverables suggests strong revenue growth, but also potentially slower collection. The 179% increase in trade creditors could indicate strategic payment stretching or simply higher volumes of trade activity.

3. Diagnosis

The Critical Incident: 2020-2022 Financial Trauma

The most significant finding in this assessment is the catastrophic decline between 2020 and 2022:

This represents a financial haemorrhage of over £8 million in shareholder value. The likely causes, given the company's status as a subsidiary of Egis Industries SAS (which acquired >75% control), include:

1. Group Restructuring: Large intercompany transactions or dividend extractions following the acquisition
2. Asset Write-downs: Potential impairment of previously inflated asset values
3. Operational Losses: Significant trading losses during the period
4. Strategic Reinvestment: Funds may have been redirected within the Egis group

The absence of a profit & loss statement (permitted under small company filing exemptions) makes definitive diagnosis impossible without further investigation.

Current Condition: Guarded Recovery

Positive Symptoms: - ✅ Cash position has nearly doubled (£622K → £1.24M) - ✅ Shareholders' funds grew by 55% (£540K → £839K) - ✅ Employee count increased (26 → 29), suggesting business expansion - ✅ Retained earnings grew by £298,783, indicating profitability - ✅ Unqualified audit opinion—no red flags from auditors - ✅ Filing compliance is current

Concerning Symptoms: - ⚠️ Current liabilities increased 83% (£861K → £1.58M) - ⚠️ Accrued expenses more than doubled (£404K → £865K) - ⚠️ Leverage ratio has worsened (1.59 → 1.88) - ⚠️ Significant concentration in contract recoverables (£659K)—revenue recognition risk - ⚠️ Company remains far below pre-2021 financial position - ⚠️ Dependency on group undertakings (£36K owed to group companies)

Systemic Assessment

4. Recommendations

Immediate Treatment (0-6 months)

1. Debtor Management Programme: With trade debtors up 58% and contract recoverables at £659K, implement rigorous credit control and collection procedures. The equivalent of 51% of annual revenue is sitting in outstanding receivables—this needs systematic follow-up.

2. Creditor Terms Review: The 179% increase in trade creditors needs investigation. Ensure the company isn't building up unpaid supplier balances that could damage relationships and credit terms.

3. Accrued Expenses Audit: Accrued expenses doubled to £865K. Understand what these represent—are they contracted commitments or uncertain provisions? This affects cash flow forecasting significantly.

Medium-term Rehabilitation (6-18 months)

4. Working Capital Policy: Establish formal working capital targets. The current ratio of 1.52 provides limited headroom. Aim for 1.8-2.0 to build resilience.

5. Cash Reserve Strategy: While cash has improved, establish a minimum cash reserve policy. The company has demonstrated vulnerability to rapid cash depletion—maintaining a 3-month operating expense reserve would be prudent.

6. Group Relationship Management: As a subsidiary of Egis Industries SAS, clarify intercompany funding arrangements. The £36K owed to group undertakings is currently small, but group dynamics may have driven the previous financial restructuring. Ensure transparent governance around group transactions.

Long-term Wellness (18+ months)

7. Revenue Diversification: As a specialist environmental and engineering consultancy (SIC codes 71122, 72190, 74901), explore whether client concentration risk exists. The significant "amounts recoverable on contracts" suggests major project dependency.

8. Profitability Analysis: With retained earnings growing by £299K on equity of £839K, the return on equity is approximately 36%—excellent on paper. However, the company needs to sustain this performance to rebuild its equity position to pre-2021 levels. At current rates, this would take approximately 25 years to recover to 2020 equity levels organically.

9. Succession Planning: Key person risk exists with the Galson family's significant involvement (Allen Everett Galson as director, Caroline Sarah-Jane Galson as director/secretary and >75% shareholder alongside Egis). Ensure business continuity plans are in place.

Prognosis

Short-term (12 months): Cautiously optimistic. The 2023 results show the patient is responding to treatment—cash is recovering, profitability has returned, and the business is growing headcount. However, the rapid increase in short-term liabilities needs careful management to prevent relapse.

Medium-term (2-3 years): Dependent on group strategy. As a subsidiary of a French multinational, Galson Sciences' future is intertwined with Egis Industries' strategic priorities. The company could continue recovering, be further integrated into group operations, or face further restructuring.

Key Risk: The company's equity position remains extremely thin compared to its historical baseline. A significant bad debt, contract dispute, or unexpected liability could push the company back into distress. The £659K in contract recoverables represents a material concentration risk.